Abstract
Lung cancer is the most commonly diagnosed malignancy and the leading cause of cancer mortality worldwide. Radiation therapy (RT) plays an important role in the management of both small cell (SCLC) and non-small cell lung cancer (NSCLC), as 50 to 60% of patients diagnosed with lung cancer will require RT during the course of their disease. In NSCLC, in addition to the use of RT in advanced stage disease, inoperable patients with early-stage disease are now being treated with highly conformal hypofractionated RT as well as radiosurgery. In SCLC, the use of thoracic chemo-RT followed by prophylactic cranial irradiation (PCI) in limited-stage disease, and the use of PCI in extensive-stage disease have improved outcomes, and patient survival has steadily increased in the past decades. This article will review the role of RT in both SCLC and NSCLC, with emphasis at the most recent advances in the field as well as the topics of controversy.
Keywords: Radiation therapy, non-small cell lung cancer, small-cell lung cancer, malignancy, radiosurgery, Inoperable Patients, Stereotactic Radiation Therapy, Chemoradiation, Palliative Radiotherapy, Thoracic Radiation Therapy
Current Respiratory Medicine Reviews
Title: Radiation Therapy in the Management of Lung Cancer
Volume: 7 Issue: 5
Author(s): Tarek Hijal, Jonathan Wan and Luis Souhami
Affiliation:
Keywords: Radiation therapy, non-small cell lung cancer, small-cell lung cancer, malignancy, radiosurgery, Inoperable Patients, Stereotactic Radiation Therapy, Chemoradiation, Palliative Radiotherapy, Thoracic Radiation Therapy
Abstract: Lung cancer is the most commonly diagnosed malignancy and the leading cause of cancer mortality worldwide. Radiation therapy (RT) plays an important role in the management of both small cell (SCLC) and non-small cell lung cancer (NSCLC), as 50 to 60% of patients diagnosed with lung cancer will require RT during the course of their disease. In NSCLC, in addition to the use of RT in advanced stage disease, inoperable patients with early-stage disease are now being treated with highly conformal hypofractionated RT as well as radiosurgery. In SCLC, the use of thoracic chemo-RT followed by prophylactic cranial irradiation (PCI) in limited-stage disease, and the use of PCI in extensive-stage disease have improved outcomes, and patient survival has steadily increased in the past decades. This article will review the role of RT in both SCLC and NSCLC, with emphasis at the most recent advances in the field as well as the topics of controversy.
Export Options
About this article
Cite this article as:
Hijal Tarek, Wan Jonathan and Souhami Luis, Radiation Therapy in the Management of Lung Cancer, Current Respiratory Medicine Reviews 2011; 7 (5) . https://dx.doi.org/10.2174/157339811797189704
DOI https://dx.doi.org/10.2174/157339811797189704 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
siRNA Delivery by Stimuli-Sensitive Nanocarriers
Current Pharmaceutical Design Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
Current Pharmaceutical Biotechnology Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer
Current Cancer Drug Targets Multi-Targeted Natural Products Evaluation Based on Biological Activity Prediction with PASS
Current Pharmaceutical Design Serum Biochemical Markers of Brain Injury
Mini-Reviews in Medicinal Chemistry TGF-β1 Causes EMT by Regulating N-Acetyl Glucosaminyl Transferases via Downregulation of Non Muscle Myosin II-A through JNK/P38/PI3K Pathway in Lung Cancer
Current Cancer Drug Targets Trizbenzim, Cu-Trizbenzim and Zn-Trizbenzim as G-Quadruplex Inducing and Stabilizing Compounds on Human Telomeric Sequence and their Anticancer Properties
Anti-Cancer Agents in Medicinal Chemistry Human Sirtuins: An Overview of an Emerging Drug Target in Age-Related Diseases and Cancer
Current Drug Targets RNAi in Clinical Studies
Current Medicinal Chemistry Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Intracellular Delivery of Nanocarriers for Cancer Therapy
Current Nanoscience Molecular Studies on Novel Antitumor Bis 1,4-Dihydropyridine Derivatives Against Lung Carcinoma and their Limited Side Effects on Normal Melanocytes
Anti-Cancer Agents in Medicinal Chemistry Cyclooxygenases in Cancer: Chemoprevention and Sensitization to Conventional Therapies
Mini-Reviews in Medicinal Chemistry Clinical and Genetic Features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) Syndrome
Current Molecular Medicine Local Gene Delivery for Cancer Therapy
Current Gene Therapy Insulin Secretagogues, Sulfonylurea Receptors and KATP Channels
Current Pharmaceutical Design Target Therapies in Pancreatic Carcinoma
Current Medicinal Chemistry Synthesis, Antioxidant, Anticancer and Antiviral Activities of Novel Quinoxaline Hydrazone Derivatives and their Acyclic C-Nucleosides
Medicinal Chemistry Garlic-Derived Allyl Sulfides in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Spongistatins as Tubulin Targeting Agents
Current Pharmaceutical Design